-
-
-
-
-
-
-
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
-
-
-
-
-
-
-
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
-
-
-
-
-
-
-
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
-
-
-
-
-
-
-
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
-
-
-
-
-
-
-
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
-
-
-
-
-
-
-
Alvotech (ALVO) and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara
-
-
-
-
-
-
-
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
-
1,159,971 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

